×
Resources » Webinars » Objective quantitative evaluation of anti-fibrotic agents in animal models
Email to GenScript

Objective quantitative evaluation of anti-fibrotic agents in animal models

Fibrosis is becoming a leading cause of death in organ injuries, particularly among aging population, without effective and safe therapies to date. One of the major hurdles in fibrosis-related drug discovery is the dependence on manual scoring for therapeutic effects of lead compounds in animal models. Here we introduce a service of animal models coupled to a digital imaging and quantitation method. The method incorporated nonlinear microscopy by second harmonic generation to produce collagen-specific images, and by two-photon excitation fluorescence to delineate tissue morphology. The imaging and subsequent analysis were validated with fibrotic diseases in liver, kidney, lung, bone marrow, and other organs, using reference compounds including Imatinib, Nintedanib, and Pirfenidone. The therapeutic effects of the compounds observed in our models were definitive and reproducible. The results correlated well with those of parallel biomarker analysis. The method is straightforward and stain-free. It provides further histological detail of disease status. We present this method as revolution in histological evaluation of anti-fibrosis drugs in pre-clinical settings.




New Targets and Models for Fibrotic Diseases
Fibrotic disease models Syngeneic Mouse Tumor Models Cell-based immune-checkpoint functional assays
  • Expertise in fibrotic disease models for liver, lung and kidney
  • Validated with clinical grade drugs
  • Biochemical and histopathological endpoints that mimic fibrotic diseases in human are measured to determine efficacy of therapeutic being tested
  • Efficacy evaluation of cancer immunotherapeutic leads
  • Reliable models for studying immune-checkpoint modulators such as anti-CTLA-4, PD-1 and PD-L1 therapeutics
  • Facilitating your drug discovery of cancer immunotherapeutics
  • Endpoint readout is IL-2 level measurements
  • Reliable models for studying immune-checkpoint modulators such as anti-CTLA-4, PD-1 and PD-L1 therapeutics
  • Clinical-grade reference antibody is provided as a positive control
  • Comprehensive data set
 
*
*
*
*